ATE510536T1 - Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen - Google Patents

Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen

Info

Publication number
ATE510536T1
ATE510536T1 AT07788436T AT07788436T ATE510536T1 AT E510536 T1 ATE510536 T1 AT E510536T1 AT 07788436 T AT07788436 T AT 07788436T AT 07788436 T AT07788436 T AT 07788436T AT E510536 T1 ATE510536 T1 AT E510536T1
Authority
AT
Austria
Prior art keywords
treatment
tissue diseases
dihydroxybenzene derivatives
reactive tissue
reactive
Prior art date
Application number
AT07788436T
Other languages
English (en)
Inventor
Sanchez Pedro Cuevas
De Tejada Gorman Inigo Saenz
Gallego Guillermo Gimenez
Frutos Javier Angulo
Lapez Luis Ignacio Rivas
Nuncio Francisco Javier Moreno
Jaen Tomas Fernando Fernandez
Puerto Rosa Maria Lozano
Garrido Antonio Romero
Lapez Serafin Valverde
Original Assignee
Action Medicines Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200602217A external-priority patent/ES2315117B1/es
Application filed by Action Medicines Sl filed Critical Action Medicines Sl
Application granted granted Critical
Publication of ATE510536T1 publication Critical patent/ATE510536T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07788436T 2006-08-16 2007-08-15 Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen ATE510536T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200602217A ES2315117B1 (es) 2006-08-16 2006-08-16 Uso de derivados 2,5-dihidroxibencenicos en la preparacion de medicamentos utiles en el tratamiento de asma.
ES200701855 2007-07-02
PCT/EP2007/058456 WO2008020042A1 (en) 2006-08-16 2007-08-15 Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases

Publications (1)

Publication Number Publication Date
ATE510536T1 true ATE510536T1 (de) 2011-06-15

Family

ID=38515369

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07788436T ATE510536T1 (de) 2006-08-16 2007-08-15 Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
AT07788431T ATE509621T1 (de) 2006-08-16 2007-08-15 Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07788431T ATE509621T1 (de) 2006-08-16 2007-08-15 Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen

Country Status (8)

Country Link
US (2) US9060966B2 (de)
EP (3) EP2056805B1 (de)
AR (5) AR062390A1 (de)
AT (2) ATE510536T1 (de)
CL (5) CL2007002388A1 (de)
ES (1) ES2495965T3 (de)
PT (3) PT2056805E (de)
WO (5) WO2008020031A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2238924B1 (es) * 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
ES2430204T3 (es) 2006-08-16 2013-11-19 AmDerma Pharmaceuticals, LLC Uso de compuestos de 2,5-dihidroxibenceno y sus derivados para el tratamiento de la rosácea
US20110196040A1 (en) 2008-02-15 2011-08-11 Action Medicines S.L. Skin Penetration Enhancing Systems for Polar Drugs
FR2951085B1 (fr) * 2009-10-09 2012-05-18 Inst Substances Vegetales Utilisation de composes phenoliques pour la deglycation des proteines
ES2385160B1 (es) * 2010-12-23 2013-05-24 Italfármaco, S.A. Compuestos con actividad inhibitoria de factores de crecimiento de fibroblastos.
ES2632012T3 (es) * 2012-02-02 2017-09-07 Invesfovea S.L. Uso del ácido 2,5-dihidroxibenceno sulfonato para el tratamiento de la degeneración macular relacionada con la edad
PL404138A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
PT3167881T (pt) * 2015-10-19 2019-12-05 Dobecure S L Etamsilato administrado localmente como medicamento
US12630788B1 (en) * 2022-10-05 2026-05-19 Futurefuel Chemical Company Dual-function additives and cleaning compositions including the same
EP4732825A1 (de) 2024-10-25 2026-04-29 BRAIN Biotech AG Antioxidant-zusammensetzung enthaltend ein zimtsäurederivat

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115648A (en) * 1974-09-13 1978-09-19 Laboratorios Del Dr. Esteve, S.A. 2,5-Dihydroxy benzene sulfonic acid mono esters
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
US4617311A (en) * 1985-05-17 1986-10-14 Eli Lilly And Company Antiasthmatic method
CH679372A5 (de) * 1989-04-07 1992-02-14 Vet Gerhard Stuker Dr Med
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5374772A (en) * 1992-12-08 1994-12-20 Hoffmann-Laroche Inc. Substituted benzoic acids, inhibitors of phospholipases A2
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
BR9807330A (pt) * 1997-02-14 2000-04-18 Kissei Pharmaceutical Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CZ20012038A3 (cs) * 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
WO2000076556A2 (en) * 1999-06-11 2000-12-21 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US20020037897A1 (en) * 2000-08-07 2002-03-28 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
JP2002193800A (ja) * 2000-12-22 2002-07-10 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
WO2002068397A1 (en) * 2001-02-28 2002-09-06 Melacure Therapeutics Ab Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
EP1429768B1 (de) * 2001-09-14 2016-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Neue arzneimittel zur inhalation
JP2005539089A (ja) * 2002-07-03 2005-12-22 ニトロメッド インコーポレーティッド ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法
RU2002120366A (ru) * 2002-08-01 2005-02-27 БиоДием Лимитед (AU) Новые производные имидазолия и фармацевтические композиции на их основе
US7553867B2 (en) * 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
AU2003212672A1 (en) * 2003-01-29 2004-08-23 Dal-Hoon Son Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
AU2004263156B2 (en) * 2003-08-07 2009-02-26 Allergan, Inc. Method for treating cachexia with retinoid ligands
GB0321228D0 (en) * 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
JP2007522079A (ja) * 2003-10-31 2007-08-09 エラン ファーマ インターナショナル リミテッド ニメスリド組成物
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives
EP1676573A1 (de) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Zusammensetzung enthaltend eine 2,5-Dihydroxybenzolsulfonsäure-Verbindung, einen Kalium Kanal Modulator und einen Phosphodiesterase 5 Inhibitor
EP1749820A1 (de) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel
EP1912938A2 (de) * 2005-08-04 2008-04-23 Novartis AG Salze von vildagliptin
CN100506804C (zh) * 2006-01-26 2009-07-01 于学敏 羟苯磺酸烷基吡嗪药物及其制备方法和应用
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
WO2007113855A1 (en) * 2006-03-30 2007-10-11 Council Of Scientific & Industrial Research A bioactive fraction from zingiber officinale and a process for the preparation thereof

Also Published As

Publication number Publication date
WO2008020031A1 (en) 2008-02-21
US20110152222A1 (en) 2011-06-23
WO2008020042A1 (en) 2008-02-21
WO2008020032A1 (en) 2008-02-21
US20080114063A1 (en) 2008-05-15
AR062396A1 (es) 2008-11-05
WO2008020032A8 (en) 2008-04-17
WO2008020033A1 (en) 2008-02-21
AR062393A1 (es) 2008-11-05
EP2056804B1 (de) 2013-05-22
AR062390A1 (es) 2008-11-05
WO2008020034A1 (en) 2008-02-21
EP2056804A1 (de) 2009-05-13
US9060966B2 (en) 2015-06-23
CL2007002388A1 (es) 2008-01-18
PT2056804E (pt) 2014-07-11
PT2056805E (pt) 2011-09-02
ES2495965T3 (es) 2014-09-17
PT2054045E (pt) 2011-08-31
ATE509621T1 (de) 2011-06-15
EP2054045B1 (de) 2011-05-18
CL2007002385A1 (es) 2008-01-18
EP2056805B1 (de) 2011-05-25
CL2007002386A1 (es) 2008-01-18
CL2007002387A1 (es) 2008-01-18
AR062395A1 (es) 2008-11-05
CL2007002392A1 (es) 2008-01-18
EP2054045A1 (de) 2009-05-06
AR062399A1 (es) 2008-11-05
EP2056805A1 (de) 2009-05-13

Similar Documents

Publication Publication Date Title
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1916964A4 (de) Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
ATE448219T1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE509621T1 (de) Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE472324T1 (de) Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties